Author information
1Division of Surgical Oncology, Department of Surgery, University of California Davis, 2279 45th Street, Sacramento, CA, 95817, USA. sgholami@ucdavis.edu.
2Division of Surgical Oncology, Department of Surgery, University of California Davis, 2279 45th Street, Sacramento, CA, 95817, USA.
3Division of Medical Oncology, Department of Medicine, University of California Irvine, Irvine, CA, USA.
4Division of Medical Oncology, Department of Medicine, University of Kansas, Kansas City, KS, USA.
5Division of Surgical Oncology, Department of Surgery, Oregon Health Sciences University, Portland, OR, USA.
Abstract
Purpose: To provide an overview of the key findings from studies in upper gastrointestinal, hepatobiliary, pancreas, and colorectal malignancies presented at ASCO GI 2022.
Methods: We reviewed the abstracts presented at ASCO GI 2022. The studies highlighted were selected by the authors based on their significant discoveries and potential impact on clinical practice.
Results and conclusion: This year's hybrid ASCO-GI symposium (2022) introduced many promising new treatment strategies in GI oncology, with several changes in clinical practice for patients with advanced hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic colorectal cancer (CRC).
Keywords: ASCO-GI symposium; Colorectal cancer; Esophygeal cancer; Gastric cancer; Hepatobiliary cancers; Pancreatic cancer.